Borderline resectable pancreatic ductal adenocarcinoma – “ABC” estimation criteria
DOI:
https://doi.org/10.5281/zenodo.15277955Keywords:
Pancreatic Head Cancer (PHC), Resectable PHC, Borderline resectable PHCAbstract
Preoperative judgement of pancreatic head cancer (PHC) resectability is still a problematic issue. More and more informative diagnostic methods are routinely used in everyday practice but none of them offers near to 100% sensitivity and specificity. It’s much easier toprove unresectability than resectability. The definition of “Borderline resectable PHC” is also a surgical challenge. The review of literature offered treats some of these problems from different points of view and gives current highlights and decision-making criteria. The final judgment of resectability is however made after surgical exploration.
References
1. Callery MP, Chang KJ, Fishman EK et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1727–1733.
2. NCCN pancreatic adenocarcinoma guidelines. Version 1. 2014. 10.
3. Isaji S, Mizuno S, Windsor JA, Bassi C et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma2017. Pancreatology. 2018; 18(1):2-11.
4. M.H. Katz, P.W. Pisters, D.B. Evans et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease J Am Coll Surg. 2008; 206: 833-846.
5. Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas 2008;36:e15-20.
6. Egawa S, Toma H, Ohigashi H et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012;41:985–992.
7. Ariyama J, Suyama M, Ogawa K, Ikari T. [Screening of pancreatic neoplasms and the diagnostic rate of small pancreatic neoplasms] Nihon Rinsho. 1986;44:1729–1734.
8. Gockel I, Domeyer M, Wollpscheck T еt al. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol. 2007; 5:44-51.
9. Peparini N, Chirletti P. Mesopancreas: a boundless structure, namely R1 risk in pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol. 2013;39(12):1303-8.
10. Sharma D, Isaji S. Mesopancreas is a misnomer: time to correct the nomenclature. J Hepatobiliary Pancreat Sci. 2016;23(12):745-749.
11. LinJY, ZhangXM, KouJT et al. Analysis of prognostic factors for pancreatic head cancer according to para‐aortic lymph node. Cancer Med. 2016; 5(10): 2701–2707.
12. Fortner JG, Kim DK, Cubilla A, Turnbull A, Pahnke LD, Shils ME. Regional pancreatectomy: En bloc pancreatic, portal vein and lymph node dissection. Ann Surg. 1977;186:42–50.
13. Fortner JG. Regional resection of cancer of the pancreas: A new surgical approach. Surgery. 1973;73:307–320.
14. Bachellier P, Nakano H, Oussoultzoglou PD, Weber JC, Boudjema K, Wolf PD. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile. Am J Surg. 2001;182:120–129.
15. Nakagohri T, Kinoshita T, Konishi Met al. Survival benefits of portal vein resection for pancreatic cancer. Am J Surg. 2003;186:149–153.
16. Van Geenen RC, ten Kate FJ, de Wit LT et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery. 2001;129:158–163.
17. Brown HM, Ahrendt SA, Komorowski RA et al. Immunohistochemistry and molecular detection of nodal micrometastases in pancreatic cancer. J Surg Res. 2001;95:141–146.
18. Henne-Bruns D, Vogel I, Luttges J et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg. 2000;24:595–601.
19. Mukaiya M, Hirata K, Satoh T et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg. 1998;22:248–252.
20. Pedrazzoli P, DiCarlo V, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998;228:508–517.
21. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized control trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355–368.
22. Ducreux M, Cuhna AS, Caramella Cet al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann. Oncol.2015; 26(Suppl 5):v56–v68.
23. Murakami Y, Uemura K, Sudo T et al. Prognostic impact of para‐aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J. Surg.2010; 34:1900–1907.
24. ShoM, Murakami Y, Motoi Fet al. Postoperative prognosis of pancreatic cancer with para‐aortic lymph node metastasis: a multicenter study on 822 patients. J. Gastroenterol. 2015;50:694–702.
25. Shimada K, Sakamoto Y, Sano T et al. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J. Am. Coll. Surg.2006; 203:345–352.
26. Paulson AS Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144:1316–1326.
27. Tamm EP, Balachandran A, Bhosale PRet al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol. Clin. North Am. 2012;50:407–428.
28. Sakai M, Nakao A, Kaneko Tet al. Para‐aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery. 2005; 137:606–611.
29. Yoshida T, Matsumoto T, Sasaki A et al. Outcome of paraaortic node‐positive pancreatic head and bile duct adenocarcinoma. Am. J. Surg. 2004; 187:736–740.
30. Ragulin-Coyne E, Carroll JE, Smith JK et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery. 2012; 152(3 Suppl. 1): S120–S127.
31. Charlson, ME et al. J Chron Dis. 1987; 40(5):373-83.
32. Kim HR, Lee CH, Kim YW et al. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47:750–4.
33. Patani O, FoulkesSL, NjieR, AspinallRJ. Prolonged cholestasis induced by endoscopic retrograde cholangiopancreatography. Frontline Gastroenterol. 2010 Jul; 1(2): 121–124.
34. Lee HM, Bonis PA, Kaplan MM. Persistent cholestatic jaundice after ERCP. Am J Gastroenterol 2006;101:204–5.
